Skip to main content
SpringerLink
Log in

Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA)

  • Original Article
  • Published:
Brain Tumor Pathology Aims and scope Submit manuscript

Abstract

Central nervous system tumors in adolescents and young adults (AYA) are rarely reported in the literature. The association with cancer predisposition syndrome is not established. Programmed death ligand 1 (PD-L1) can predict the potential response of patients to immunotherapy. A link between mismatch repair protein deficiency (MMRP-D) and response to immunotherapy is established. P53 is reported to be positive in MMRD-D cases. We aim to investigate the frequency of MMRP-D in AYA with high-grade glioma and any potential association with PD-L1. A total of 96 cases were tested including 49 (51.0%) cases of glioblastoma. Six cases (6.25%) were MMRP-D, 17 (17.7%) were PD-L1 positive, mostly in grade IV tumors (8.7% in grade III compared to 26% in grade IV, p value = 0.027), and 69 (71.9%) were P3 positive. None of the MMRP-D cases expressed PD-L1. P53-positive cases were mostly MMRP proficient (n = 67; 74.4%, p value 0.051). Fourteen cases (28.7%) were positive for both PD-L1 and P53, while p53-positive grade IV tumors were mostly associated with negative PD-L1 (n = 29, 58%, p value = 0.043). MMRP deficiency does not appear to be prevalent in high-grade glioma in AYA. Expression of PD-L1 in a quarter of cases might suggest a role for immunotherapy in high-grade glioma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ostrom QT, Gittleman H, de Blank PM, Finlay JL, Gurney JG, McKean-Cowdin R, Stearns DS, Wolff JE, Liu M, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2016) American brain tumor association adolescent and young adult primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro Oncol 18(Suppl 1):i1–i50

    Article  Google Scholar 

  2. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B, Biology and Clinical Trials Subgroups of the US National Cancer Institute Progress Review Group in Adolescent and Young Adult Oncology (2008) The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer 8(4):288–298

    Article  CAS  Google Scholar 

  3. Zapotocky M, Ramaswamy V (2018) Adolescents and young adults with brain tumors in the context of molecular advances in neuro-oncology. Pediatr Blood Cancer 65(2):e26861

    Article  Google Scholar 

  4. Bleyer A, Budd T, Montello M (2006) Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer 107(7 Suppl):1645–1655

    Article  Google Scholar 

  5. Georgakis MK, Panagopoulou P, Papathoma P, Tragiannidis A, Ryzhov A, Zivkovic-Perisic S, Eser S, Taraszkiewicz L, Sekerija M, Zagar T, Antunes L, Zborovskaya A, Bastos J, Florea M, Coza D, Demetriou A, Agius D, Strahinja RM, Sfakianos G, Nikas I, Kosmidis S, Razis E, Pourtsidis A, Kantzanou M, Dessypris N, Petridou ET (2017) Central nervous system tumours among adolescents and young adults (15–39 years) in Southern and Eastern Europe: registration improvements reveal higher incidence rates compared to the US. Eur J Cancer 86:46–58

    Article  Google Scholar 

  6. Xie C, Sheng H, Zhang N, Li S, Wei X, Zheng X (2016) Association of MSH6 mutation with glioma susceptibility, drug resistance and progression. Mol Clin Oncol 5(2):236–240

    Article  CAS  Google Scholar 

  7. Stark AM, Doukas A, Hugo HH, Mehdorn HM (2010) The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma. Neurol Res 32(8):816–820

    Article  Google Scholar 

  8. Li GM (2008) Mechanisms and functions of DNA mismatch repair. Cell Res 18(1):85–98

    Article  CAS  Google Scholar 

  9. Leung SY, Chan TL, Chung LP, Chan AS, Fan YW, Hung KN, Kwong WK, Ho JW, Yuen ST (1998) Microsatellite instability and mutation of DNA mismatch repair genes in gliomas. Am J Pathol 153(4):1181–1188

    Article  CAS  Google Scholar 

  10. Daniel P, Sabri S, Chaddad A, Meehan B, Jean-Claude B, Rak J, Abdulkarim BS (2019) Temozolomide induced hypermutation in glioma: evolutionary mechanisms and therapeutic opportunities. Front Oncol 9:41

    Article  Google Scholar 

  11. Lang FF, Miller DC, Koslow M, Newcomb EW (1994) Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors. J Neurosurg 81(3):427–436

    Article  CAS  Google Scholar 

  12. Leung SY, Yuen ST, Chan TL, Chan AS, Ho JW, Kwan K, Fan YW, Hung KN, Chung LP, Wyllie AH (2000) Chromosomal instability and p53 inactivation are required for genesis of glioblastoma but not for colorectal cancer in patients with germline mismatch repair gene mutation. Oncogene 19(35):4079–4083

    Article  CAS  Google Scholar 

  13. Amayiri N, Tabori U, Campbell B, Bakry D, Aronson M, Durno C, Rakopoulos P, Malkin D, Qaddoumi I, Musharbash A, Swaidan M, Bouffet E, Hawkins C, Al-Hussaini M (2016) High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan. Int J Cancer 138(2):380–385

    Article  CAS  Google Scholar 

  14. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520

    Article  CAS  Google Scholar 

  15. Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB (2016) Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol 18(10):1357–1366

    Article  CAS  Google Scholar 

  16. Hodges TR, Ott M, Xiu J, Gatalica Z, Swensen J, Zhou S, Huse JT, de Groot J, Li S, Overwijk WW, Spetzler D, Heimberger AB (2017) Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol 19(8):1047–1057

    Article  CAS  Google Scholar 

  17. Lee V, Murphy A, Le DT, Diaz LA Jr (2016) Mismatch repair deficiency and response to immune checkpoint blockade. Oncologist 21(10):1200–1211

    Article  CAS  Google Scholar 

  18. Joyce JA (2005) Therapeutic targeting of the tumor microenvironment. Cancer Cell 7(6):513–520

    Article  CAS  Google Scholar 

  19. Schiffer D, Annovazzi L, Casalone C, Corona C (2018) Glioblastoma: microenvironment and niche concept. Cancers 11(1):5

    Article  Google Scholar 

  20. Bazzoni R, Bentivegna A (2019) Role of notch signaling pathway in glioblastoma pathogenesis. Cancers 11(3):292

    Article  CAS  Google Scholar 

  21. Hovinga KE, Shimizu F, Wang R, Panagiotakos G, Van Der Heijden M, Moayedpardazi H, Correia AS, Soulet D, Major T, Menon J, Tabar V (2010) Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate. Stem Cells 28(6):1019–1029

    Article  CAS  Google Scholar 

  22. Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M, Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ (2017) Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun 8(1):592

    Article  CAS  Google Scholar 

  23. Zhu C, Zhuang W, Chen L, Yang W, Ou WB (2020) Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer. Transl Lung Cancer Res 9(1):111–138

    Article  CAS  Google Scholar 

  24. Li Y, He M, Zhou Y, Yang C, Wei S, Bian X, Christopher O, Xie L (2019) The prognostic and clinicopathological roles of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis. Front Pharmacol 10:139

    Article  CAS  Google Scholar 

  25. Xue S, Song G, Yu J (2017) The prognostic significance of PD-L1 expression in patients with glioma: a meta-analysis. Sci Rep 7(1):4231

    Article  Google Scholar 

  26. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (2016) WHO classification of tumours of the central nervous system, 4th edition revised, 4th edn. IARC, Geneva

    Google Scholar 

  27. O'Regan T, Chau K, Tatton M, Smith T, Parry S, Bissett I (2013) Immunochemistry screening for Lynch syndrome in colorectal adenocarcinoma using an initial two antibody panel can replace a four antibody panel. N Z Med J 126(1382):70–77

    PubMed  Google Scholar 

  28. Zeng J, Zhang XK, Chen HD, Zhong ZH, Wu QL, Lin SX (2016) Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas. Oncotarget 7(8):8944–8955

    Article  Google Scholar 

  29. Stark AM, Nabavi A, Mehdorn HM, Blomer U (2005) Glioblastoma multiforme-report of 267 cases treated at a single institution. Surg Neurol 63(2):162–169 

    Article  Google Scholar 

  30. Diwanji TP, Engelman A, Snider JW, Mohindra P (2017) Epidemiology, diagnosis, and optimal management of glioma in adolescents and young adults. Adolesc Health Med Ther 8:99–113

    Article  Google Scholar 

  31. Papageorgiou GI, Razis ED (2020) CNS tumors in adolescents and young adults: the need for a holistic specialized approach. JCO Oncol Pract 16(4):155–162

    Article  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge the King Hussein Cancer Center scientific intramural fund, Ms. Sereen Salim Al-Khuffash for the technical effort and Ms. Dalia Al-Rimawi for her help with statistical analysis.

Author information

Authors and Affiliations

  1. Department of Pathology, Mu’tah University, Kerak, Jordan

    Ghadeer Almuhaisen

  2. Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan

    Yazan Alhalaseh

  3. Office of Scientific Affairs and Research, King Hussein Cancer Center, Amman, Jordan

    Razan Mansour & Amer Abu-Shanab

  4. Department of Pathology and Laboratory Medicine, King Hussein Cancer Center, 202 Queen Rania Al-Abdullah Street, Al-Jubaiha, P.O. Box 1269, Amman, 11941, Jordan

    Sura Al-Ghnimat & Maysa Al-Hussaini

Authors
  1. Ghadeer Almuhaisen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yazan Alhalaseh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Razan Mansour
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amer Abu-Shanab
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sura Al-Ghnimat
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maysa Al-Hussaini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Maysa Al-Hussaini.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Almuhaisen, G., Alhalaseh, Y., Mansour, R. et al. Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA). Brain Tumor Pathol 38, 14–22 (2021). https://doi.org/10.1007/s10014-020-00379-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10014-020-00379-7

Keywords

Search

Navigation